AXSM
Axsome Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$207.78
−3.03%Next report
Analyst consensus
- Next report date
- Nov 2, 2026
- EPS estimate
- -$0.49
- Revenue estimate
- $258.3M
Latest reported
- Last report date
- Aug 10, 2026
- EPS actual
- -$0.99
- EPS estimate
- -$0.89
- Revenue actual
- $216.4M
- Revenue estimate
- $221.1M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- -3.9%
- Revenue beats (12Q)
- 3
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $280
- PT range
- $251 – $316
- Analysts
- 9
8 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 10, 2026 | -$0.89 | -$0.99 | Miss -10.98% | $216.4M |
| May 4, 2026 | -$0.85 | -$1.26 | Miss -48.24% | $189.4M |
| Feb 18, 2025 | -$1.00 | -$0.96 | Beat 4.00% | $118.8M |
| Feb 20, 2024 | -$1.21 | -$0.73 | Beat 39.67% | $71.5M |
| Feb 27, 2023 | -$1.18 | -$1.28 | Miss -8.47% | $24.4M |
| Aug 9, 2022 | -$1.19 | -$1.06 | Beat 10.92% | $8.8M |
| May 2, 2022 | -$1.02 | -$1.03 | Miss -0.98% | — |
| Mar 1, 2022 | -$0.99 | -$0.90 | Beat 9.09% | — |
| Mar 1, 2021 | -$0.73 | -$0.78 | Miss -6.85% | — |
| Nov 5, 2020 | -$0.58 | -$0.58 | In line | — |
| May 8, 2020 | -$0.60 | -$0.88 | Miss -46.67% | — |
| Mar 12, 2020 | -$0.51 | -$0.71 | Miss -39.22% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 2, 2026